Figure 3 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results

Figure 3 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results

<p>Association of perioperative changes in biological markers with RFS (<b>A</b>) by categories of Ki67 relative change, (<b>B</b>) by categories of Ki67 absolute change, (<b>C</b>) by baseline TILs, (<b>D</b>) by surgery TILs. RFS is represented...

Descripció completa

Guardat en:

Dades bibliogràfiques
Autor principal:	Nigel Bundred (15046233) (author)
Altres autors:	Nuria Porta (15029895) (author), Adrian Murray Brunt (15046236) (author), Angela Cramer (5870894) (author), Andrew Hanby (25460) (author), Abeer M. Shaaban (15046239) (author), Emad A. Rakha (7957955) (author), Anne Armstrong (15045410) (author), Ramsey I. Cutress (15046242) (author), David Dodwell (15046245) (author), Marie A. Emson (15046248) (author), Abigail Evans (7421527) (author), Sue M. Hartup (15046251) (author), Kieran Horgan (15030513) (author), Sarah E. Miller (15046254) (author), Stuart A. McIntosh (11368948) (author), James P. Morden (7594370) (author), Jay Naik (15046257) (author), Sankaran Narayanan (15046260) (author), Jane Ooi (15046263) (author), Anthony I. Skene (15046266) (author), David A. Cameron (6277425) (author), Judith M. Bliss (8827107) (author)
Publicat:	2025
Matèries:	Cancer Cancer Detection and Diagnosis Clinical Research and Trials Biomarkers Prognostic biomarkers Breast Cancer Clinical Trial Results Phase II clinical trials Precision Medicine
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars

Figure 1 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
per: Nigel Bundred (15046233)
Publicat: (2025)

Figure 2 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
per: Nigel Bundred (15046233)
Publicat: (2025)

Table 1 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
per: Nigel Bundred (15046233)
Publicat: (2025)

Table 2 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
per: Nigel Bundred (15046233)
Publicat: (2025)

Figure 1 from A Phase II Study of Perioperative Avelumab plus Chemotherapy for Patients with Resectable Gastric Cancer or Gastroesophageal Junction Cancer – The MONEO Study
per: Maria Alsina (21718246)
Publicat: (2025)

Figure 2 from A Phase II Study of Perioperative Avelumab plus Chemotherapy for Patients with Resectable Gastric Cancer or Gastroesophageal Junction Cancer – The MONEO Study
per: Maria Alsina (21718246)
Publicat: (2025)

Figure 3 from A Phase II Study of Perioperative Avelumab plus Chemotherapy for Patients with Resectable Gastric Cancer or Gastroesophageal Junction Cancer – The MONEO Study
per: Maria Alsina (21718246)
Publicat: (2025)

Table 1 from A Phase II Study of Perioperative Avelumab plus Chemotherapy for Patients with Resectable Gastric Cancer or Gastroesophageal Junction Cancer – The MONEO Study
per: Maria Alsina (21718246)
Publicat: (2025)

Figure 1 from Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies
per: Hyun Jung Lee (22117439)
Publicat: (2025)

Figure 2 from Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies
per: Hyun Jung Lee (22117439)
Publicat: (2025)

Figure 3 from Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies
per: Hyun Jung Lee (22117439)
Publicat: (2025)

Figure S1 from Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies
per: Hyun Jung Lee (22117439)
Publicat: (2025)

Figure S2 from Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies
per: Hyun Jung Lee (22117439)
Publicat: (2025)

Table 1 from Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies
per: Hyun Jung Lee (22117439)
Publicat: (2025)

Supplementary Table 1 from Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies
per: Hyun Jung Lee (22117439)
Publicat: (2025)

Supplementary Table 2 from Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies
per: Hyun Jung Lee (22117439)
Publicat: (2025)

Table S1-S8 from Urinary Tumor DNA MRD Analysis to Identify Responders to Neoadjuvant Immunotherapy in Muscle-invasive Bladder Cancer
per: Ruiyun Zhang (17142498)
Publicat: (2025)

Figure S1 from High-Throughput Peptide Arrays Identify Potential Diagnostic Autoantibody Signatures in Early-Stage Lung Adenocarcinoma
per: Rongrong Luo (14855518)
Publicat: (2025)

Figure S2 from High-Throughput Peptide Arrays Identify Potential Diagnostic Autoantibody Signatures in Early-Stage Lung Adenocarcinoma
per: Rongrong Luo (14855518)
Publicat: (2025)

Figure S5 from High-Throughput Peptide Arrays Identify Potential Diagnostic Autoantibody Signatures in Early-Stage Lung Adenocarcinoma
per: Rongrong Luo (14855518)
Publicat: (2025)

Figure S6 from High-Throughput Peptide Arrays Identify Potential Diagnostic Autoantibody Signatures in Early-Stage Lung Adenocarcinoma
per: Rongrong Luo (14855518)
Publicat: (2025)

Supplementary Figure 1 from Immune and Growth Factor Signaling Pathways Are Associated with Pathologic Complete Response to an Anti–Type I Insulin-like Growth Factor Receptor Regimen in Patients with Breast Cancer
per: Emmanuel F. Petricoin (22436166)
Publicat: (2025)

Supplementary Tables 1 from Immune and Growth Factor Signaling Pathways Are Associated with Pathologic Complete Response to an Anti–Type I Insulin-like Growth Factor Receptor Regimen in Patients with Breast Cancer
per: Emmanuel F. Petricoin (22436166)
Publicat: (2025)

Supplementary Table S4 from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with <i>MDM2</i> Amplification: An Open-Label Phase Ib/II Study
per: Takafumi Koyama (15035714)
Publicat: (2025)

Supplementary Table S5A from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with <i>MDM2</i> Amplification: An Open-Label Phase Ib/II Study
per: Takafumi Koyama (15035714)
Publicat: (2025)

Supplementary Table S5B from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with <i>MDM2</i> Amplification: An Open-Label Phase Ib/II Study
per: Takafumi Koyama (15035714)
Publicat: (2025)

Supplementary Table S6 from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with <i>MDM2</i> Amplification: An Open-Label Phase Ib/II Study
per: Takafumi Koyama (15035714)
Publicat: (2025)

Supplementary Figure S1 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
per: Kala Visvanathan (14952973)
Publicat: (2025)

Supplementary Figure S2 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
per: Kala Visvanathan (14952973)
Publicat: (2025)

Supplementary Figure S3 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
per: Kala Visvanathan (14952973)
Publicat: (2025)

Supplementary Figure S4 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
per: Kala Visvanathan (14952973)
Publicat: (2025)

Supplementary Figure S5 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
per: Kala Visvanathan (14952973)
Publicat: (2025)

Figure 2 from A First-in-Human Study of ATM Inhibitor Lartesertib as Monotherapy in Patients with Advanced Solid Tumors
per: Lillian L. Siu (14851075)
Publicat: (2025)

Figure 3 from A First-in-Human Study of ATM Inhibitor Lartesertib as Monotherapy in Patients with Advanced Solid Tumors
per: Lillian L. Siu (14851075)
Publicat: (2025)

Supplementary Figure S1 from A First-in-Human Study of ATM Inhibitor Lartesertib as Monotherapy in Patients with Advanced Solid Tumors
per: Lillian L. Siu (14851075)
Publicat: (2025)

Supplementary Figure S2 from A First-in-Human Study of ATM Inhibitor Lartesertib as Monotherapy in Patients with Advanced Solid Tumors
per: Lillian L. Siu (14851075)
Publicat: (2025)

Supplementary Figure S3 from A First-in-Human Study of ATM Inhibitor Lartesertib as Monotherapy in Patients with Advanced Solid Tumors
per: Lillian L. Siu (14851075)
Publicat: (2025)

Supplementary Figure S4 from A First-in-Human Study of ATM Inhibitor Lartesertib as Monotherapy in Patients with Advanced Solid Tumors
per: Lillian L. Siu (14851075)
Publicat: (2025)

Supplementary Figure S5 from A First-in-Human Study of ATM Inhibitor Lartesertib as Monotherapy in Patients with Advanced Solid Tumors
per: Lillian L. Siu (14851075)
Publicat: (2025)

Supplementary Table S5 from A First-in-Human Study of ATM Inhibitor Lartesertib as Monotherapy in Patients with Advanced Solid Tumors
per: Lillian L. Siu (14851075)
Publicat: (2025)